|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CTAGE5 |
Gene summary for CTAGE5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CTAGE5 | Gene ID | 4253 |
| Gene name | MIA SH3 domain ER export factor 2 | |
| Gene Alias | CTAGE5 | |
| Cytomap | 14q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | O15320 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4253 | CTAGE5 | P1T-E | Human | Esophagus | ESCC | 3.64e-03 | 3.38e-01 | 0.0875 |
| 4253 | CTAGE5 | P2T-E | Human | Esophagus | ESCC | 2.94e-21 | 2.65e-01 | 0.1177 |
| 4253 | CTAGE5 | P4T-E | Human | Esophagus | ESCC | 2.72e-24 | 5.74e-01 | 0.1323 |
| 4253 | CTAGE5 | P5T-E | Human | Esophagus | ESCC | 4.45e-18 | 2.71e-01 | 0.1327 |
| 4253 | CTAGE5 | P8T-E | Human | Esophagus | ESCC | 2.03e-41 | 6.93e-01 | 0.0889 |
| 4253 | CTAGE5 | P9T-E | Human | Esophagus | ESCC | 1.57e-13 | 3.58e-01 | 0.1131 |
| 4253 | CTAGE5 | P10T-E | Human | Esophagus | ESCC | 6.16e-16 | 1.47e-01 | 0.116 |
| 4253 | CTAGE5 | P11T-E | Human | Esophagus | ESCC | 1.67e-15 | 4.78e-01 | 0.1426 |
| 4253 | CTAGE5 | P12T-E | Human | Esophagus | ESCC | 4.39e-86 | 1.69e+00 | 0.1122 |
| 4253 | CTAGE5 | P15T-E | Human | Esophagus | ESCC | 9.97e-24 | 5.81e-01 | 0.1149 |
| 4253 | CTAGE5 | P16T-E | Human | Esophagus | ESCC | 3.01e-09 | 2.18e-01 | 0.1153 |
| 4253 | CTAGE5 | P17T-E | Human | Esophagus | ESCC | 3.20e-06 | 2.39e-01 | 0.1278 |
| 4253 | CTAGE5 | P20T-E | Human | Esophagus | ESCC | 3.25e-18 | 3.72e-01 | 0.1124 |
| 4253 | CTAGE5 | P21T-E | Human | Esophagus | ESCC | 1.16e-23 | 2.89e-01 | 0.1617 |
| 4253 | CTAGE5 | P22T-E | Human | Esophagus | ESCC | 1.11e-16 | 2.31e-01 | 0.1236 |
| 4253 | CTAGE5 | P23T-E | Human | Esophagus | ESCC | 1.32e-20 | 5.05e-01 | 0.108 |
| 4253 | CTAGE5 | P24T-E | Human | Esophagus | ESCC | 1.21e-10 | 2.18e-01 | 0.1287 |
| 4253 | CTAGE5 | P26T-E | Human | Esophagus | ESCC | 1.58e-42 | 7.73e-01 | 0.1276 |
| 4253 | CTAGE5 | P27T-E | Human | Esophagus | ESCC | 7.57e-26 | 5.89e-01 | 0.1055 |
| 4253 | CTAGE5 | P28T-E | Human | Esophagus | ESCC | 1.85e-14 | 1.41e-01 | 0.1149 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CTAGE5 | SNV | Missense_Mutation | c.2038N>A | p.Val680Met | p.V680M | O15320 | protein_coding | tolerated(0.13) | benign(0.119) | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| CTAGE5 | SNV | Missense_Mutation | c.1537N>A | p.Pro513Thr | p.P513T | O15320 | protein_coding | deleterious(0.04) | possibly_damaging(0.856) | TCGA-A2-A0YI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Femara | SD | |
| CTAGE5 | SNV | Missense_Mutation | novel | c.1972G>A | p.Gly658Arg | p.G658R | O15320 | protein_coding | deleterious(0.01) | possibly_damaging(0.519) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| CTAGE5 | SNV | Missense_Mutation | c.2126N>G | p.Phe709Cys | p.F709C | O15320 | protein_coding | deleterious(0.01) | possibly_damaging(0.896) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR | |
| CTAGE5 | SNV | Missense_Mutation | rs764463597 | c.1694N>A | p.Arg565Gln | p.R565Q | O15320 | protein_coding | deleterious(0) | probably_damaging(0.919) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CTAGE5 | SNV | Missense_Mutation | rs750487896 | c.1112N>T | p.Ser371Leu | p.S371L | O15320 | protein_coding | deleterious(0.02) | benign(0.125) | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CTAGE5 | SNV | Missense_Mutation | novel | c.298N>G | p.Gln100Glu | p.Q100E | O15320 | protein_coding | tolerated(0.2) | benign(0.012) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
| CTAGE5 | SNV | Missense_Mutation | c.1901C>T | p.Ser634Phe | p.S634F | O15320 | protein_coding | deleterious(0.03) | possibly_damaging(0.865) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CTAGE5 | SNV | Missense_Mutation | novel | c.365N>A | p.Thr122Lys | p.T122K | O15320 | protein_coding | deleterious(0.03) | benign(0.444) | TCGA-PE-A5DD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | CR | |
| CTAGE5 | deletion | Frame_Shift_Del | novel | c.926delN | p.Tyr309SerfsTer2 | p.Y309Sfs*2 | O15320 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |